Ticker > Company >

Biogen Pharmachem share price

Biogen Pharmachem Industries Ltd.

BSE: 531752 SECTOR: Trading  79.75 K   200   42

0.92
0 0
BSE: Today, 04:00 PM

Price Summary

Today's High

₹ 0.94

Today's Low

₹ 0.92

52 Week High

₹ 1.48

52 Week Low

₹ 0.75

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

83.04 Cr.

Enterprise Value

83.02 Cr.

No. of Shares

90.26 Cr.

P/E

68.66

P/B

0.61

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  1.5

CASH

0.02 Cr.

DEBT

0 Cr.

Promoter Holding

0 %

EPS (TTM)

₹  0.01

Sales Growth

0%

ROE

3.48 %

ROCE

3.48%

Profit Growth

323.86 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 YearNA
3 Year-100%
5 Year-100%

Profit Growth

1 Year323.86%
3 Year47.43%
5 Year252.75%

ROE%

1 Year3.48%
3 Year1.43%
5 Year0.23%

ROCE %

1 Year3.48%
3 Year1.43%
5 Year0.24%

Debt/Equity

0

Price to Cash Flow

42.7

Interest Cover Ratio

0

CFO/PAT (5 Yr. Avg.)

11.8370314957697

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 0.00 0.00
Mar 2025 0.00 0.00
Dec 2024 0.00 0.00
Sep 2024 0.00 0.00
Jun 2024 0.00 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 47.4267782273792% for the Past 3 years.
  • Company is virtually debt free.
  • Company’s PEG ratio is 0.212653574655507.
  • The company has an efficient Cash Conversion Cycle of 0 days.
  • The company has a good cash flow management; CFO/PAT stands at 11.8370314957697.

 Limitations

  • The company has shown a poor revenue growth of -100% for the Past 3 years.
  • Company has a poor ROE of 1.43243827125563% over the past 3 years.
  • Company has a poor ROCE of 1.43262807890085% over the past 3 years
  • Tax rate is low at 0.
  • The company has a low EBITDA margin of -19.8833129626078% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 66.7951.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales -0.09 0 0 1.35 1.54
Total Expenditure 0.07 0.35 0.54 0.17 0.2
Operating Profit -0.16 -0.35 -0.54 1.18 1.35
Other Income 0 -0.65 0.23 0 0
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.16 -1 -0.31 1.18 1.35
Tax 0 0 0 0 0
Profit After Tax -0.16 -1 -0.31 1.18 1.35
Adjusted EPS (Rs) 0 -0.02 0 0.02 0.01

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 0 1.62 2.47 0 0
Total Expenditure 0.12 3.23 2.49 0.46 0.45
Operating Profit -0.12 -1.6 -0.02 -0.46 -0.45
Other Income 0 0 0.01 0.91 2.38
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.12 -1.6 -0.01 0.46 1.93
Tax 0 0 0 0 0
Net Profit -0.12 -1.6 -0.01 0.46 1.93
Adjusted EPS (Rs.) 0 -0.02 0 0.01 0.03

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 65.26 65.26 65.26 65.26 65.26
Total Reserves -9.51 -11.12 -11.13 -10.67 -8.74
Borrowings 0.31 0 0 0 0
Other N/C liabilities 0 0 0 0 0
Current liabilities 0.04 0.11 0.82 0.24 0.3
Total Liabilities 56.09 54.25 54.95 54.83 56.82
Assets
Net Block 0 0 0 0 0
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 6.45 9.49 6.95 8.85 5.44
Loans & Advances 41.6 42.2 46.06 45.82 51.29
Other N/C Assets 0 0 0 0 0
Current Assets 8.04 2.56 1.93 0.15 0.09
Total Assets 56.09 54.25 54.95 54.83 56.82
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -0.12 -1.6 -0.01 0.46 1.93
Adjustment 0 0 0 0 0
Changes in Assets & Liabilities -1.1 5.55 1.41 1.25 0.01
Tax Paid 0 0 0 0 0
Operating Cash Flow -1.21 3.95 1.4 1.7 1.94
Investing Cash Flow 1.54 -3.64 -1.32 -1.66 -2.06
Financing Cash Flow -0.32 -0.31 0 0 0
Net Cash Flow 0 0 0.08 0.05 -0.11

Corporate Actions

Investors Details

 No Promoters Data available for this company.Report us
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 100.00 100.00 100.00 100.00 100.00
anamika dealers private l... 3.39 3.39 3.39 3.39 2.45
compact fashions private ... 3.05 3.05 3.05 3.05 2.21
interface financial servi... - - - - 9.31
kamna coal private limite... 1.57 1.57 1.57 1.57 1.13
omega coal private limite... 6.99 6.99 6.99 6.99 5.05
others - - - - 0.01
parichay infrastructure l... - - - - 9.08
rama shiva lease finance ... - - - - 9.31
subhrashi agencies privat... 3.39 3.39 3.39 3.39 2.45

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

 No Latest News available for this company.Report us

Biogen Pharmachem Stock Price Analysis and Quick Research Report. Is Biogen Pharmachem an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Biogen Pharmachem stock price today is Rs 0.92. Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Biogen Pharmachem . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Biogen Pharmachem has a PE ratio of 68.6567164179104 which is high and comparatively overvalued .

  • Share Price: - The current share price of Biogen Pharmachem is Rs 0.92. One can use valuation calculators of ticker to know if Biogen Pharmachem share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Biogen Pharmachem has ROA of 3.4585 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Biogen Pharmachem has a Current ratio of 0.3044 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Biogen Pharmachem has a ROE of 3.4753 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Biogen Pharmachem has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: - Biogen Pharmachem has reported revenue growth of 0 % which is poor in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Biogen Pharmachem for the current financial year is 0 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Biogen Pharmachem is Rs 0 and the yield is 0 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Biogen Pharmachem is Rs 0.0134 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Biogen Pharmachem in Ticker for free. Also, one can get the intrinsic value of Biogen Pharmachem by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Biogen Pharmachem
X